| Literature DB >> 36253550 |
José A Velilla1, Matthew R Volpe2, Grace E Kenney2, Richard M Walsh3,4, Emily P Balskus2,5, Rachelle Gaudet6.
Abstract
Colibactin, a DNA cross-linking agent produced by gut bacteria, is implicated in colorectal cancer. Its biosynthesis uses a prodrug resistance mechanism: a non-toxic precursor assembled in the cytoplasm is activated after export to the periplasm. This activation is mediated by ClbP, an inner-membrane peptidase with an N-terminal periplasmic catalytic domain and a C-terminal three-helix transmembrane domain. Although the transmembrane domain is required for colibactin activation, its role in catalysis is unclear. Our structure of full-length ClbP bound to a product analog reveals an interdomain interface important for substrate binding and enzyme stability and interactions that explain the selectivity of ClbP for the N-acyl-D-asparagine prodrug motif. Based on structural and biochemical evidence, we propose that ClbP dimerizes to form an extended substrate-binding site that can accommodate a pseudodimeric precolibactin with its two terminal prodrug motifs in the two ClbP active sites, thus enabling the coordinated activation of both electrophilic warheads.Entities:
Year: 2022 PMID: 36253550 DOI: 10.1038/s41589-022-01142-z
Source DB: PubMed Journal: Nat Chem Biol ISSN: 1552-4450 Impact factor: 16.174